Eli Lilly shares rise on revenue beat, raised outlook
Steady2 outlets reported this in 2 reports over 2 days
Wed, 5 August 2026Sat, 8 August 2026
What it is about
Eli LillyDavid RicksMounjaro To China National Reimbursement Drug ListBoehringer IngelheimDan SkovronskyLimmatech BiologicsIlya YuffaPatrik JonssonDave RicksJake Van NaardenLucas MontarceTriumphLilly InternationalVaccine CompanyBridge ProgramUnited Arab EmiratesSaudi ArabiaAmericansChinaIreland
Who published it, and when
original reportfirst to report
proactiveinvestors.com
themarketsdaily.com
5 Aug, 09:37over 3 days8 Aug, 16:04
How it spread - 2 original reports
Wed, 5 August 2026
1 report- proactiveinvestors.com09:37first to report
Eli Lilly and Co (NYSE:LLY) shares rose nearly 7% in early trading Wednesday after the drugmaker reported second quarter results that topped Wall Street...
Sat, 8 August 2026
1 report- themarketsdaily.com16:04
Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered growth across key products and major geographies, advanced its pipeline and […]